Global Breast Cancer Monoclonal Antibodies Market Growth 2024 , Forecast To 2033
7 Mar, 2024
The breast cancer monoclonal antibodies market size has grown strongly in recent years, from $18.97 billion in 2023 to $20.18 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. This growth is attributed to the rising prevalence of breast cancer, increasing awareness of breast cancer monoclonal antibodies, growing clinical efficacy, and patient demand. It is expected to continue growing, reaching $27.8 billion in 2028 at a CAGR of 8.3%. This expansion is driven by emerging targets, biosimilars, combination therapies, and factors such as global incidence and aging population, alongside personalized medicine. Major trends in the forecast period include advances in early breast cancer detection, immunotherapy integration, liquid biopsies, companion diagnostics, adjuvant and neoadjuvant therapies, and long-term survivorship support.
Global Breast Cancer Monoclonal Antibodies Market Key Driver
Rising breast cancer incidences are expected to drive the breast cancer monoclonal antibody market’s growth. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of breast cancer cases increased from 284,200 in 2021 to 300,590 in 2023, reflecting a growth of 5.76%. Thus, the rising prevalence of breast cancer globally is expected to boost the growth of the breast cancer monoclonal antibody market.
Get A Free Sample Of The Global Breast Cancer Monoclonal Antibodies Market ReportGlobal Breast Cancer Monoclonal Antibodies Market Segments
The breast cancer monoclonal antibodies market covered in this report is segmented –
1) By Product: Naked Mabs, Conjugated Mabs
2) By Treatment: Chemotherapy, Surgery & Radiation Therapy, Targeted Therapy, Biologic Therapy, Hormone Therapy
3) By End-User: Hospitals, Retail Pharmacies
By Geography: The countries covered in the breast cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the breast cancer monoclonal antibodies market in 2023. The regions covered in the breast cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Major Breast Cancer Monoclonal Antibodies Industry Players
Amgen Inc.; Mylan N.V.; Merck & Co. Inc.; Novartis AG; GlaxoSmithKline plc.; Daiichi Sankyo Company Ltd.; Biocad; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Array BioPharma Inc.; Celldex Therapeutics Inc.; Celltrion Inc.; F. Hoffmann-La Roche AG; Immunomedics Inc.; MacroGenics Inc.; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.; Puma Biotechnology Inc.; Seattle Genetics Inc.; AstraZeneca plc; Eddingpharm; Eisai Co. Ltd.; Galena Biopharma Inc.; ImmunoGen Inc.; Eli Lilly and Company; AbbVie Inc.; Johnson & Johnson; Mersana Therapeutics Inc.; Immunocore Limited; Immunovative Therapies Ltd.
Get The Full Global Breast Cancer Monoclonal Antibodies Market ReportBreast Cancer Monoclonal Antibodies Market Overview
Breast cancer monoclonal antibodies (mAbs) refer to the use of antibodies in the treatment of both early-stage and advanced breast cancer. It functions by identifying and locating particular proteins on cancer cells. Every MAB recognises a different protein. Therefore, different MABs must be created to target various cancer types. They kill the cancer cell in various ways depending on the protein they are targeting.